AMGEN at the American Heart Association's (AHA) Scientific Sessions 2022

Welcome to the Amgen Medical Virtual Exhibit

Data Presentations

Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial

Michelle L. O’Donoghue, et al.


Investigational product. Safety and effectiveness have not been established


Risk for Incident Coronary Heart Disease Associated with High Lipoprotein(a) by Levels of Factor VIII and High-Sensitivity C-reactive Protein

Lisandro D. Colantonio, et al.


Some abstracts/presentations reflect data, analyses, and/or views of third parties that have not been supported by or adopted by Amgen.